Whom to Test for H. pylori
Test all individuals with current or past peptic ulcer disease, uninvestigated dyspepsia, gastric MALT lymphoma, family history of gastric cancer, and those planning long-term NSAID or aspirin use—and proactively screen high-risk populations including first-generation immigrants from high-prevalence countries and racial/ethnic minorities (Hispanics, African Americans, East Asians). 1
High-Priority Clinical Indications (Test These Patients)
The 2022 consensus guidelines provide the most current framework, with 100% expert agreement on several key populations 1:
Mandatory Testing Groups:
- Active or past gastric/duodenal ulcers (100% agreement, high evidence) - This prevents ulcer recurrence and complications 1
- Uninvestigated dyspepsia (100% agreement, high evidence) - Test before empiric PPI therapy 1
- Gastric MALT lymphoma (100% agreement, moderate evidence) - H. pylori eradication is first-line treatment, achieving cure in 60-80% of early-stage cases 2
- Family history of gastric cancer (100% agreement, moderate evidence) - Critical for cancer prevention in at-risk individuals 1
Before Starting Medications:
- Prior to long-term NSAID therapy - Eradication is mandatory in patients with peptic ulcer history and beneficial before starting NSAIDs 2
- Aspirin users with ulcer history - Testing prevents gastropathy; residual bleeding risk after successful eradication is very low even without gastroprotection 2
High-Risk Populations for Proactive Screening
The most recent guidelines emphasize a shift toward proactive population-based testing 1:
Demographic Risk Factors:
- First-generation immigrants from high-prevalence areas (82% agreement, high evidence) - In the U.S., prevalence is 2.6-fold higher in Hispanics and 3.2-fold higher in East Asians compared to the general population 1
- High-risk racial/ethnic groups (91% agreement) - Latino, African American, and other minorities in the U.S. 1
- Family members in same household as H. pylori-positive patients (91% agreement, moderate evidence) - Prevents person-to-person transmission and protects against reinfection 1
Population-Level Screening:
- Young adults in high-prevalence populations (84% agreement) - Screen before development of atrophic gastritis and intestinal metaplasia, and to reduce transmission to children 1
- Populations with high gastric cancer prevalence (84% agreement) - Countries like Japan, Korea, Taiwan, and China have implemented or are planning population-wide eradication programs 1
Additional Clinical Scenarios
Strongly Recommended:
- Family history of peptic ulcer disease (91% agreement, moderate evidence) 1
- Long-term PPI therapy - Eradication heals gastritis and prevents progression to atrophic gastritis, though evidence for cancer risk reduction is lacking 2, 3
- Unexplained iron-deficiency anemia - Clear association with H. pylori 2
- Idiopathic thrombocytopenic purpura (ITP) - Evidence supports testing 2
- Vitamin B12 deficiency - Linked to H. pylori infection 2
Not Recommended:
- GERD patients - H. pylori status has no effect on symptom severity or treatment efficacy; eradication does not exacerbate GERD 2
- Routine testing for thyroxine or L-dopa malabsorption - While H. pylori affects bioavailability, no evidence of direct clinical benefit from testing 2
Important Clinical Caveats
Testing strategy matters: The 2022 guidelines formally recognize H. pylori gastritis as an infectious disease requiring eradication whenever diagnosed 1. This represents a paradigm shift—the infection provides no proven benefits to the host and carries significant risk.
Predictive performance: Research shows that individual risk factors have modest predictive value (AUROC 0.57-0.59 for race/ethnicity and immigrant status), but combining multiple risk factors improves diagnostic performance (AUROC 0.64) 4. This supports the comprehensive approach outlined in current guidelines.
Avoid virulence factor testing: While certain H. pylori virulence factors and host genetic polymorphisms affect disease risk, there is no evidence that testing for these factors is useful for individual patient management 2.
Test-and-treat approach: Once infection is documented, always eradicate—the current consensus is that H. pylori gastritis carries significant risk with no proven benefits 1.